Three groups of alteration which cause acute Myeloid Leukemia, a cancer of the white blood cells, have been known by the scientists.
The scientists advise their work on mice, published in Nature Genetics, could lead to new treatments. Almost two thousand people in
are diagnosed with acute myeloid leukemia every year. The charity Leukemia and Lymphoma Research said the study offered an important imminent. Britain
During the disease, the bone marrow, which makes blood cells, begins to turn out undeveloped white blood cells which imbalances of the blood. The white blood cells are not correctly made so they cannot clash infection and there are too some red blood cells to take oxygen almost the body. The disease could be worsening within few weeks if left untreated.
The scientist team at the Welcome Trust Sanger Institute examined that how this type of leukemia happens because they say there had been short progress in producing new medicines.
The most changes involved d in the cancer is to the Npm1 gene. By controlling this gene on in blood cells in mice, the scientists were able to appear that it enhanced the capability of cells to repair them, which is an indication of cancer. So far only a third of mice went on to build up leukemia. The researchers accomplished other variations must also play a role.
They arbitrarily changed genes in mice, with a system known as insertional mutagenesis. By watching at mice which created cancer, they could then draw which changes were concerned. They also found two extra types of transformation. One involves cell partition and development, while the other changes the cell's surroundings.
Dr George Vassiliou, consultant hematologist from the Welcome Trust Sanger Institute, said they had "research severe measures that happen when the cancer creates. Making out the biological methods in turn means we can see for new medicines to overturn the procedure." Getting new medicines to patients could take many years, but what can occur immediately is using medicines which are already on the shelf, but in a more hit way."
Scientific Director at Leukemia & Lymphoma Research, Dr David Grant, said: "New medicines which hit particular genetic changes are confirming ever more helpful in treatment of blood cancers.
"It offers a possible model for the growth of new medicines for this dreadful disease in the days to come."